GSK's asthma drug Nucala gets speedy review for rare blood disorder
GlaxoSmithKline’s asthma drug Nucala may not be on the same tier as rival Regeneron’s Dupixent, but it has scored a speedy review for use in a rare blood disorder.
First approved in 2015 for severe eosinophilic asthma, Nucala (known chemically as mepolizumab) targets IL-5. The British drugmaker on Wednesday disclosed that the monoclonal antibody secured priority review from the FDA for patients with hypereosinophilic syndrome (HES) — a group of life-threatening inflammatory disorders characterized by a persistent overproduction of a type of white blood cell called eosinophils.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.